All News

Medically integrated dispensaries could be in violation of the Medicare Physician Self-Referral Law, known as the Stark Law, due to an interpretation of the law released in 2021.

Patients with comorbid acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) expressed a desire to discuss treatment options and maintain normalcy; they were not willing to have conversations involving their prognosis and future.

A retrospective analysis surveys the treatment landscape and patterns of patients with paroxysmal nocturnal hemoglobinuria (PNH), illuminating high hospitalization rates and emergency department use despite the availability of multiple treatment options.

A systematic review of randomized controlled trials and prospective cohort studies concludes that sleep could be a prognostic component of lower back pain, but better evidence is needed.

Dupilumab and topical corticosteroids can be used to treat symptoms in children with atopic dermatitis (AD).

The increased risk is likely due to the underlying cancer disease and adjuvant treatments, researchers find.

Pandemic-era policies that made it easier for patients to receive opioid addiction treatment will continue permanently; the Biden administration is facing pressure from Democrats and reproductive health groups to make sure the first OTC birth control pill is affordable; a FDA expert panel on Friday is set to resume the debate over how to make pulse oximeters more accurate for people with darker skin.

Although rates of opioid use disorder (OUD) are higher than previous estimates, OUD was relatively stable or decreasing over time in patients with HIV.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

The findings not only underscore the efficacy of 2 major interventions—Behavioral Activation Psychotherapy (BA) and Antidepressant Medication Management (MEDS)—but also support patient autonomy in choosing their preferred path to mental well-being.

Bevey Miner, executive vice president of health care strategy and policy, Consensus Cloud Solutions, discusses the complex landscape of proposed health care rules, and the potential impact of CMS' Advancing Interoperability and Prior Authorizations Rule.

A large-scale, population-based study examined patterns of disease-modifying therapy (DMT) exposure in pregnant patients with MS since 2010, revealing increased occurrences and the need for future studies to examine the impact of newer-developed DMTs.

Patients with colorectal cancer (CRC) could participate in telehealth and e-health interventions to promote their sexual health, although efficacy of these interventions needs to be further studied.

This systematic review found COVID-19 disruptions on clinical outcomes in those with diabetes to be more pronounced for females, younger people, and those a part of racial and ethnic minority groups.

Inhaled chronic obstructive pulmonary disease (COPD) medications prescribed before surgery in patients with early-stage non–small cell lung cancer (NSCLC) were associated with both short- and long-term outcomes.

Days spent obtaining health care outside the home may show access to needed care, but also add up to substantial time, effort, and cost burdens to patients and those who care for them, according to the study authors.

CMS released the proposed 2025 Advance Notice for the Medicare Advantage (MA) and Medicare Part D Prescription Drug Programs; there have been 561 deaths related to the use of Philips’ recalled ventilators and machines for treating obstructive sleep apnea since 2021; the FDA warned the public against copycat eye drops due to infection risk.

Medicare-eligible patients with cutaneous squamous cell carcinoma (cSCC) could save on health care costs by utilizing the 40-gene expression profile (40-GEP) to guide treatment decisions.

The group emphasizes the importance of management strategies that consider 5 types, or groups, of pulmonary hypertension (PH), including 4 types secondary to other conditions.

Children and adolescents were at higher risk for myopic maculopathy progression if they had worse best-corrected visual acuity and longer axial length, among other risk factors.

A national analysis found significant disparities between non-binary transgender individuals and cisgender individuals related to mental health.

This analysis compared outcomes among patients who have Duchenne muscular dystrophy (DMD) and commercial insurance or Medicaid, focusing on how these differ between patients in clinical trials and those who receive treatment post approval.

Aducanumab’s accelerated approval was controversial and insurance coverage of the expensive therapy was limited.

Drug prices in the US increased 4.4% annually and median out-of-pocket (OOP) costs increased 9.6% annually from 2009 to 2018, but there was no direct link between these amounts for individual drugs.

Sickle cell disease (SCD) will be the first focus of the Cell and Gene Therapy (CGT) Access Model; the FTC has challenged the validity of over 100 drug product patents to help increase competition and potentially lower prices; the rate of infectious syphilis cases in the US rose 9% in 2022.

Having multiple readmissions for diabetes ketoacidosis (DKA) was more likely to occur among patients with type 1 diabetes (T1D) with substance use disorder or who previously were incarcerated.

However, the association between familial hypercholesterolemia variants and coronary heart disease slightly weakened after adjusting for baseline low-density lipoprotein cholesterol (LDL-C) level and became statistically insignificant after adjusting for cumulative past LDL-C exposure.

Most of the research suggests combination therapies might be the best option for many patients who have acute myeloid leukemia (AML).

Researchers have retrospectively analyzed data from nearly 60 patients with ocular myasthenia gravis (MG) not adequately responding to oral prednisone, finding that both intravenous (IV) methylprednisolone and tacrolimus monotherapy helped reduce symptoms.

Outcomes were evaluated among veterans treated for non–small cell lung cancer (NSCLC) from 2017 to 2020 with durvalumab, a PD-L1 inhibitor.